Extra Indications Approved For Celltrion’s Remsima SC
Subcutaneous Biosimilar Infliximab Also Helps Minimize COVID-19 Risk
The European Commission has granted an extension to Celltrion’s pan-European marketing authorization for subcutaneous biosimilar infliximab, which now covers indications for IBD and ankylosing spondylitis.
